Author: Visco, Carlo; Marcheselli, Luigi; Mina, Roberto; Sassone, Marianna; Guidetti, Anna; Penna, Domenico; Cattaneo, Chiara; Bonuomo, Valentina; Busca, Alessandro; Ferreri, Andrés José MarÃa; Bruna, Riccardo; Petrucci, Luigi; Cairoli, Roberto; Salvini, Marco; Bertù, Lorenza; Ladetto, Marco; Pilerci, Sofia; Pinto, Antonello; Ramadan, Safaa; Marchesi, Francesco; Cavo, Michele; Arcaini, Luca; Coviello, Elisa; Romano, Alessandra; Musto, Pellegrino; Massaia, Massimo; Fracchiolla, Nicola; Marchetti, Monia; Scattolin, Annamaria; Tisi, Maria Chiara; Cuneo, Antonio; Porta, Matteo Della; Trentin, Livio; Turrini, Marco; Gherlinzoni, Filippo; Tafuri, Agostino; Galimberti, Sara; Bocchia, Monica; Cardinali, Valeria; Cilloni, Daniela; Corso, Alessandro; Armiento, Daniele; Luigi, Rigacci; Barbera, Elettra Ortu La; Gambacorti-Passerini, Carlo; Visani, Giuseppe; Vallisa, Daniele; Venditti, Adriano; Selleri, Carmine; Conconi, Annarita; Tosi, Patrizia; Lanza, Francesco; Candoni, Anna; Krampera, Mauro; Corradini, Paolo; Passamonti, Francesco; Merli, Francesco
Title: A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study Cord-id: jeimv4qo Document date: 2021_10_15
ID: jeimv4qo
Snippet: Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behaviour and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of deat
Document: Lymphoma represents a heterogeneous hematological malignancy (HM), which is characterized by severe immunosuppression. Patients diagnosed of coronavirus disease (COVID-19) during the course of HM have been described to have poor outcome, with only few reports specifically addressing lymphoma patients. Here, we investigated the clinical behaviour and clinical parameters of a large multicenter cohort of adult patients with different lymphoma subtypes, with the aim of identifying predictors of death. The study included 856 patients, of whom 619 were enrolled prospectively in a 1-year frame and were followed-up for a median of 66 days (range 1-395). Patients were managed as outpatient (not admitted cohort, n=388), or required hospitalization (n=468), and median age was 63 years (range 19-94). Overall, the 30- and 100-days mortality was 13% (95%CI 11-15%) and 23% (95%CI 20-27%), respectively. Anti-lymphoma treatment, including anti-CD20 containing regimens, did not impact on survival. Patients with Hodgkin's lymphoma had the more favourable survival, but this was partly related to significantly younger age. The time interval between lymphoma diagnosis and COVID-19 was inversely related to mortality. Multivariable analysis recognized 4 easy-to-use factors (age, gender, lymphocyte, and platelet count) that were associated with risk of death, both in the admitted and in the not-admitted cohort (HR 3.79 and 8.85 for the intermediate and high-risk group, respectively). Overall, our study shows that patients should not be deprived of the best available treatment for their underlying disease, and indicates which patients are at higher risk of death. This study was registered with ClinicalTrials.gov, NCT04352556.
Search related documents:
Co phrase search for related documents- absolute lymphocyte count and active disease status: 1
- absolute lymphocyte count and active therapy: 1
- absolute lymphocyte count and active treatment: 1, 2, 3
- absolute lymphocyte count and acute inflammation: 1
- absolute lymphocyte count and acute respiratory distress syndrome: 1, 2, 3, 4
- active disease and acute impact: 1
- active disease and acute inflammation: 1, 2
- active disease and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
- active disease and adaptive innate: 1, 2, 3
- active disease and adaptive innate immune system: 1
- active disease status and acute respiratory distress syndrome: 1
- active disease status and adaptive innate: 1
- active disease status and adaptive innate immune system: 1
- active therapy and acute impact: 1, 2
- active therapy and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7
- active treatment and acute impact: 1, 2, 3
- active treatment and acute inflammation: 1
- active treatment and acute respiratory distress syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11
- acute impact and adaptive innate: 1
Co phrase search for related documents, hyperlinks ordered by date